ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -28 مورد

Estimated sensitivity, specificity, and cancer-specific deaths averted for each colorectal cancer screening strategy

Estimated sensitivity, specificity, and cancer-specific deaths averted for each colorectal cancer screening strategy
Sensitivity, specificity, and cancer-specific deaths averted for each screening strategy.

COL: colonoscopy; CTC: computed tomography colonography; FIT: fecal immunochemical test; FIT-DNA: multitargeted stool deoxyribonucleic acid test; gFOBT: guaiac-based fecal occult blood test; SIG: sigmoidoscopy.

* Assumes screening from ages 50 to 75 years, including 100% adherence, complete follow-up without delay, and appropriate surveillance. Ranges reflect results from 3 models.

Data from:
  1. Zauber A, Knudsen A, Rutter CM, et al. Evaluating the Benefits and Harms of Colorectal Cancer Screening Strategies: A Collaborative Modeling Approach. AHRQ Publication No. 14-05203-EF-2. Rockville, MD: Agency for Healthcare Research and Quality; October 2015.
  2. Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. JAMA 2016; 315:2595.
Graphic 116366 Version 8.0